Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on peripheral nerve repair, regeneration, and restoration of function. The AXGN news feed on this page aggregates company announcements, earnings releases, regulatory updates, and other disclosures related to its nerve repair portfolio and corporate activities.
Recent Axogen news has highlighted revenue growth, gross margin trends, and updated financial guidance, as well as developments in reimbursement coverage for nerve repair procedures using allografts and synthetic conduits. Earnings releases and accompanying conference calls provide details on revenue by quarter, profitability metrics, cash and investment balances, and management’s commentary on market development and commercial execution across extremities, oral and maxillofacial, head and neck, and breast reconstruction markets.
Regulatory milestones are a key theme in AXGN news. The company has reported FDA acceptance and subsequent approval of its Biologics License Application for Avance (acellular nerve allograft-arwx), including information on the Prescription Drug User Fee Act (PDUFA) review timeline, accelerated approval indications, and anticipated commercial availability under the biologic framework. Updates on professional society position statements and clinical practice guidelines recognizing nerve allograft as a standard medical practice option for peripheral nerve defects also appear in company communications.
Investors and observers can also find notices about Axogen’s participation in healthcare and investor conferences, where management presents the company’s strategy and meets with institutional investors. By following AXGN news here, readers can monitor financial results, regulatory progress, reimbursement developments, and corporate events that shape Axogen’s peripheral nerve repair business over time.
Axogen (Nasdaq: AXGN) priced an upsized underwritten public offering of 4,000,000 common shares at $31.00 per share, generating gross proceeds of about $124 million (assuming no exercise of the option). The underwriters have a 30-day option to buy up to 600,000 additional shares at the public offering price less discounts and commissions. The offering is expected to close on January 23, 2026, subject to customary conditions.
Axogen intends to use net proceeds to pay off and terminate its term loan facility with Oberland Capital, and for working capital, capital expenditures and other general corporate purposes. Wells Fargo Securities and Mizuho lead the deal; Canaccord Genuity and Raymond James are co-managers.
Axogen (Nasdaq: AXGN) announced a proposed underwritten public offering of $85.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $12.75 million of shares. All shares will be sold by Axogen and the offering is subject to market and other conditions with no assurance of completion or final terms. Wells Fargo Securities and Mizuho are lead book-runners; Canaccord Genuity and Raymond James are co-managers. Axogen intends to use net proceeds for early payoff and termination of its Oberland Capital term loan facility, working capital, capital expenditures and general corporate purposes. The offering is being made under an automatic Form S-3ASR registration statement that became effective on January 21, 2026.
Axogen (NASDAQ: AXGN) reported preliminary unaudited results for Q4 and full-year 2025. Q4 revenue is expected to be approximately $59.9 million (+21.3% vs Q4 2024) and full-year revenue is expected to be approximately $225.2 million (+20.2% vs FY 2024). Gross margin is expected to be above 74%, despite approximately $1.9 million of one-time costs tied to the FDA BLA approval of Avance® (67% of those costs are non-cash stock-compensation vesting).
Cash, cash equivalents, restricted cash, and investments are expected to total about $45.5 million as of December 31, 2025, an increase of approximately $6.0 million year-over-year. The company received FDA BLA approval for Avance® on December 3, 2025. Final audited results are expected in late February 2026.
Axogen (NASDAQ: AXGN) will present at the J.P. Morgan 2026 Healthcare Conference. Management is scheduled to present on Thursday, January 15, 2026 at 10:30 AM Pacific Standard Time. A live audio webcast will be available via the company’s investor relations site at ir.axogeninc.com.
This provides investors and analysts an opportunity to hear management commentary on recent developments and strategic priorities directly from company leadership.
Axogen (NASDAQ: AXGN) announced FDA approval of the Biologics License Application for AVANCE (acellular nerve allograft–arwx), cleared to treat adult and pediatric patients aged 1 month or older with sensory, mixed, and motor peripheral nerve discontinuities. The FDA granted indications for sensory nerve gaps >25mm and for mixed and motor nerve discontinuities under the Accelerated Approval pathway based on static two‑point discrimination data. Continued approval requires confirmatory studies to verify clinical benefit. Axogen said the approval moves Avance from a human tissue classification to a biologic and strengthens its regulatory footing. Commercial availability is expected early Q2 2026, while Avance remains available under the current tissue framework until then.
Axogen (NASDAQ: AXGN) announced management will participate in three investor conferences in Nov–Dec 2025: a Jefferies Global Healthcare Conference fireside chat and 1x1s on Nov 18, 2025 at 4:30 PM GMT, Canaccord Genuity MedTech 1x1 meetings on Nov 20, 2025, and a Piper Sandler Annual Healthcare Conference presentation and 1x1s with the presentation on Dec 2, 2025 at 12:30 PM ET.
Webcasts and replays are available via the Investors page at www.axogeninc.com; replays will be archived for 90 days.
Axogen (NASDAQ: AXGN) reported third quarter 2025 results with Q3 revenue $60.1M, up 23.5% YoY and 6.0% QoQ. Gross margin was 76.6%; net income was $0.7M ($0.01/share) versus a net loss in Q3 2024. Adjusted net income was $6.1M ($0.12/share) and adjusted EBITDA was $9.2M. Cash and investments totaled $39.8M at September 30, 2025.
The company raised full‑year revenue guidance to at least 19% growth / $222.8M, reiterated full‑year gross margin of 73–75% and expects to be net cash flow positive for 2025. FDA BLA approval for Avance Nerve Graft is now anticipated by December 5, 2025. Expanded payer coverage added ~18.1M lives in 2025, with commercial coverage >64%.
Axogen (NASDAQ: AXGN) will report its 2025 third quarter financial results on Wednesday, October 29, 2025 before the market opens.
The company said management will host an investor conference call and webcast at 8:00 a.m. ET following the release. Phone participants may dial toll free at (877) 407-0993 or direct at (201) 689-8795. A live webcast, archived replay, and presentation slides will be available on the company’s Investors page at www.axogeninc.com.
Axogen (NASDAQ: AXGN), a leader in peripheral nerve function surgical solutions, has announced its participation in four major upcoming investor conferences in September 2025. The company will host a fireside chat at the Cantor Global Healthcare Conference on September 3 at 3:20 PM ET, which will be available via webcast.
Management will also conduct one-on-one investor meetings at the Wells Fargo Healthcare Conference (September 4), Morgan Stanley Annual Global Healthcare Conference (September 10), and Lake Street BIG 9 Conference (September 11). All webcast events will be accessible through Axogen's investor relations website and archived for 90 days.
Axogen (NASDAQ:AXGN) announced that the FDA has extended the PDUFA goal date for its Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5, 2025. The extension follows the FDA's designation of Axogen's recent submission, which included new manufacturing and facility data, as a Major Amendment to its BLA.
The FDA plans to provide feedback on product labeling in November 2025. This extension allows the agency additional time to review the substantial new information submitted as part of the company's response to an FDA information request, supporting the transition of Avance Nerve Graft from a tissue product to a BLA-approved biologic.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
